Journal
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
Volume 28, Issue 3, Pages 465-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2019.02.012
Keywords
Adoptive T-cell transfer; Tumor-infiltrating lymphocytes; Neoantigens; Gene engineered T-cell receptor; Chimeric antigen receptor T cell
Funding
- NATIONAL CANCER INSTITUTE [ZIABC011337] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The use of immunotherapies for solid and hematologic malignancies has demonstrated durable antitumor effects. Use of checkpoint inhibitors allows for immunologic reactivation of the adaptive immune system against tumor-specific neoantigens and effective rejection. Recent developments in adoptive transfer of T cells has shown effective immune rejection of solid malignancies and durable regression. Adoptive cell transfer involves extraction of in vivo T lymphocytes, selection for or introduction of tumor reactive cells, in vitro expansion, and delivery of the T-cell product back to the patient. This article discusses the different approaches, challenges, and further directions of adoptive T -cell transfer in solid malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available